Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6052432 | 0.84 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2TSHRRAB9AHPGD | |
| SCHEMBL798337 | 0.84 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2TSHRRAB9AHPGD | |
| SCHEMBL4578766 | 0.79 | RIPK2 (0.49) | ALDH1A1SMN1; SMN2TSHRRAB9AHPGD | |
| SCHEMBL10340563 | 0.77 | HTT (0.60) | ALDH1A1SMN1; SMN2TSHRRAB9AHPGD | |
| SCHEMBL16787630 | 0.76 | ALDH1A1 (0.82) | ALDH1A1SMN1; SMN2TSHRRAB9AHPGD | |
| SCHEMBL1062661 | 0.76 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2TSHRRAB9AHPGD | |
| SCHEMBL15167569 | 0.76 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2TSHRRAB9AHPGD | |
| SCHEMBL27273816 | 0.76 | HTT (0.58) | ALDH1A1SMN1; SMN2TSHRRAB9AHPGD | |
| SCHEMBL13766911 | 0.75 | HTT (0.58) | ALDH1A1SMN1; SMN2TSHRRAB9AHPGD | |
| SCHEMBL26978013 | 0.75 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2TSHRRAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | claimed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | MKI67, CCNB1, RB1 | ALDH1A1 440/4885SMN1; SMN2 2840/4885TSHR 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.